The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 564.00
Bid: 560.00
Ask: 568.00
Change: 4.00 (0.71%)
Spread: 8.00 (1.429%)
Open: 560.00
High: 568.00
Low: 560.00
Prev. Close: 560.00
GHH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ITL signs manufacturing agreement with OrganOx

13 Mar 2019 07:00

RNS Number : 6541S
Gooch & Housego PLC
13 March 2019
 

 

 13 March 2019

 

RNS REACH

 

 

 

Gooch & Housego PLC

("Gooch & Housego" or the "Company")

 

ITL signs manufacturing agreement with OrganOx

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of optical components and systems, announces that its life science business ITL has been awarded a five-year contract from OrganOx Limited for the manufacture of metra, an innovative medical device that allows livers for transplant to be stored and transported at body temperature.

The metra system operates by supplying a donated liver with oxygenated blood, anti-clotting drugs and assorted nutrients whilst keeping the organ at a stable temperature (37°C). It has the potential to significantly reduce the number of livers that are discarded due to damage incurred by cold storage or a lack of oxygen.

OrganOx, which was founded in 2008 as a spin-out company from Oxford university, has already gained marketing approval for metra in Europe and is in late stage clinical trials in the US.

Tom Cole, managing director of ITL, said: "We are delighted to be working in partnership with OrganOx on this ground-breaking project. This agreement is yet another important milestone positioning metra as one of the most promising transplantation candidates in late-stage development. This collaboration marks the beginning of what I'm sure will be a very exciting journey for both ITL and OrganOx."

Craig Marshall, CEO of OrganOx, said: "This agreement is strategically important to OrganOx as we prepare to penetrate the US market. I have a manufacturing background and I know the importance of working with the best partners in the supply chain. ITL is a great fit with OrganOx given their track record of successfully bringing medical devices to the market coupled with UK HQ with a presence in the US and in China."

University Hospitals Birmingham is one of the European liver transplant units to have conducted clinical research into metra, which was featured last year in the BBC TV series Surgeons: At the Edge of Life.

Darius Mirza, professor of transplant surgery at University Hospitals Birmingham, said: "In the 30 years I've been involved with transplantation, there have been three or four events which have been game changers and I'm absolutely certain we are looking at a game changer that will change the way we practise organ storage and transplantation."

 

 

For further information contact: -

 

Mark Webster / Andrew Boteler

Gooch & Housego PLC

01460 256440

Mark Court / Sophie Wills / Catriona Flint

Buchanan

020 7466 5000

Patrick Robb / David Anderson

Investec Bank plc

020 7597 5970

 

 

 

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAQLLFFKXFEBBZ
Date   Source Headline
4th Apr 20247:00 amRNSHalf Year Trading Update
18th Mar 20242:36 pmRNSDivestment of EM4
29th Feb 20247:00 amRNSDirector/PDMR Shareholding
27th Feb 20243:26 pmRNSNotification of Major Holdings
22nd Feb 20244:07 pmRNSNotification of Major Holdings
21st Feb 202412:31 pmRNSResult of AGM
21st Feb 202410:28 amRNSDirector/PDMR Shareholding
21st Feb 20249:43 amRNSDirector/PDMR Shareholding
21st Feb 20247:00 amRNSAGM Trading Update
12th Jan 20247:00 amRNSAnnual Report and Notice of AGM
10th Jan 20247:00 amRNSGrant of LTIP Awards
9th Jan 202411:53 amRNSNotification of Major Holdings
8th Jan 20243:57 pmRNSNotification of Major Holdings
4th Jan 20243:20 pmRNSDirector/PDMR Shareholding
5th Dec 20237:00 amRNSResults for the year ended 30 September 2023
8th Nov 20237:00 amRNSNotification of Full Year Results
23rd Oct 20232:23 pmRNSHolding(s) in Company
3rd Oct 20237:00 amRNSFull Year Trading Update
2nd Oct 20232:44 pmRNSHolding(s) in Company
9th Aug 20236:15 pmRNSDirector/PDMR Shareholding
31st Jul 20238:22 amRNSHolding(s) in Company
21st Jul 202311:58 amRNSCompletion of Acquisition and Issue of Equity
19th Jul 20237:00 amRNSAcquisition of Artemis Optical
23rd Jun 20234:11 pmRNSHolding(s) in Company
21st Jun 202310:26 amRNSDirector/PDMR Shareholding
20th Jun 20236:00 pmRNSAcquisition of GS Optics
6th Jun 20237:00 amRNSInterim Results
23rd May 20237:00 amRNSNotification of Half Year Results
3rd May 20238:56 amRNSIssue of Equity
4th Apr 20237:00 amRNSHalf Year Trading Update
30th Mar 20239:33 amRNSHolding(s) in Company
15th Mar 202312:00 pmRNSAppointment of Non-Executive Director
3rd Mar 20234:37 pmRNSHolding(s) in Company
2nd Mar 20231:10 pmRNSHolding(s) in Company
1st Mar 20239:44 amRNSHolding(s) in Company
22nd Feb 20231:50 pmRNSResult of AGM
22nd Feb 20237:00 amRNSAGM Trading Update
8th Feb 202312:59 pmRNSHolding(s) in Company
9th Jan 202311:44 amRNSGrant of LTIP Awards
21st Dec 202210:02 amRNSPosting of Annual Report and Notice of AGM
20th Dec 202212:30 pmRNSDirector/PDMR Shareholding
6th Dec 20224:26 pmRNSDirector/PDMR Shareholding
6th Dec 20229:38 amRNSDirector/PDMR Shareholding
6th Dec 20227:00 amRNSResults for the year ended 30 September 2022
25th Nov 20223:17 pmRNSHolding(s) in Company
23rd Nov 20224:27 pmRNSHolding(s) in Company
18th Nov 20222:20 pmRNSHolding(s) in Company
2nd Nov 20227:00 amRNSNotification of Full Year Results
27th Oct 202212:56 pmRNSHolding(s) in Company
18th Oct 20222:50 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.